{"id":"ebastine","rwe":[{"pmid":"41833879","year":"2026","title":"Repositioning of nonsedating antihistamine Ebastine for anti-lung adenocarcinoma based on EGFR/ERBB2 dual-targeting strategy.","finding":"","journal":"European journal of pharmacology","studyType":"Clinical Study"},{"pmid":"41707943","year":"2026","title":"Efficacy and Safety of Oral Antihistamines for Allergic Rhinitis: Network Meta-Analysis.","finding":"","journal":"The journal of allergy and clinical immunology. In practice","studyType":"Clinical Study"},{"pmid":"41686612","year":"2026","title":"Severe exfoliative dermatitis induced by apalutamide in a mHSPC patient: A case report.","finding":"","journal":"Medicine","studyType":"Clinical Study"},{"pmid":"41645758","year":"2026","title":"Ebastine targets HER2/HER3 signaling and cancer stem cell traits to overcome trastuzumab resistance in HER2‑positive breast cancer.","finding":"","journal":"International journal of molecular medicine","studyType":"Clinical Study"},{"pmid":"41603723","year":"2026","title":"Dose-Dependent Effect of the Histamine 1 Receptor Antagonist Ebastine in Patients With Non-Constipated Irritable Bowel Syndrome.","finding":"","journal":"Neurogastroenterology and motility","studyType":"Clinical Study"}],"tags":[{"label":"ebastine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Histamine H1 receptor","category":"target"},{"label":"HRH1","category":"gene"},{"label":"HTR2A","category":"gene"},{"label":"ADRA2C","category":"gene"},{"label":"R06AX22","category":"atc"},{"label":"Active","category":"status"},{"label":"Allergic rhinitis","category":"indication"},{"label":"Chronic idiopathic urticaria","category":"indication"},{"label":"Histamine Agents","category":"pharmacology"},{"label":"Histamine Antagonists","category":"pharmacology"},{"label":"Histamine H1 Antagonists","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":229.792,"date":"","count":168,"signal":"COVID-19","source":"DrugCentral FAERS","actionTaken":"Reported 168 times (LLR=230)"},{"llr":138.702,"date":"","count":134,"signal":"Urticaria","source":"DrugCentral FAERS","actionTaken":"Reported 134 times (LLR=139)"},{"llr":92.324,"date":"","count":20,"signal":"Allergy test positive","source":"DrugCentral FAERS","actionTaken":"Reported 20 times (LLR=92)"},{"llr":91.155,"date":"","count":69,"signal":"Angioedema","source":"DrugCentral FAERS","actionTaken":"Reported 69 times (LLR=91)"},{"llr":82.931,"date":"","count":18,"signal":"Endocrine ophthalmopathy","source":"DrugCentral FAERS","actionTaken":"Reported 18 times (LLR=83)"},{"llr":79.889,"date":"","count":58,"signal":"Drug reaction with eosinophilia and systemic symptoms","source":"DrugCentral FAERS","actionTaken":"Reported 58 times (LLR=80)"},{"llr":67.157,"date":"","count":17,"signal":"Gallbladder polyp","source":"DrugCentral FAERS","actionTaken":"Reported 17 times (LLR=67)"},{"llr":66.444,"date":"","count":19,"signal":"Nasal ulcer","source":"DrugCentral FAERS","actionTaken":"Reported 19 times (LLR=66)"},{"llr":63.145,"date":"","count":30,"signal":"Dental caries","source":"DrugCentral FAERS","actionTaken":"Reported 30 times (LLR=63)"},{"llr":62.683,"date":"","count":16,"signal":"Toxic shock syndrome","source":"DrugCentral FAERS","actionTaken":"Reported 16 times (LLR=63)"},{"llr":51.929,"date":"","count":16,"signal":"Eyelid disorder","source":"DrugCentral FAERS","actionTaken":"Reported 16 times (LLR=52)"},{"llr":51.71,"date":"","count":32,"signal":"Diabetes mellitus inadequate control","source":"DrugCentral FAERS","actionTaken":"Reported 32 times (LLR=52)"},{"llr":45.801,"date":"","count":17,"signal":"Mean cell haemoglobin increased","source":"DrugCentral FAERS","actionTaken":"Reported 17 times (LLR=46)"},{"llr":42.955,"date":"","count":16,"signal":"Swelling of eyelid","source":"DrugCentral FAERS","actionTaken":"Reported 16 times (LLR=43)"},{"llr":42.29,"date":"","count":25,"signal":"Vitamin D deficiency","source":"DrugCentral FAERS","actionTaken":"Reported 25 times (LLR=42)"}],"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_fixedAt":"2026-03-30T16:54:39.637883","_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=EBASTINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:50:26.661674+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:50:32.375543+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=EBASTINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:50:32.775774+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Histamine H1 receptor inverse agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:50:33.833403+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL305660/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:50:33.487582+00:00"}},"allNames":"bastel","offLabel":[],"synonyms":["ebastine","bastel","ebastel","ebastin","erostin","kestine"],"timeline":[{"date":"1990-01-01","type":"positive","source":"DrugCentral","milestone":"YEAR INTRODUCED approval"}],"approvals":[{"date":"1990-01-01","orphan":false,"company":"","regulator":"YEAR INTRODUCED"}],"brandName":"Bastel","ecosystem":[{"indication":"Allergic rhinitis","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"antazoline","slug":"antazoline","company":"Novartis"},{"name":"astemizole","slug":"astemizole","company":""}],"globalPrevalence":null},{"indication":"Chronic idiopathic urticaria","otherDrugs":[{"name":"astemizole","slug":"astemizole","company":""},{"name":"cetirizine","slug":"cetirizine","company":"J And J Consumer Inc"},{"name":"desloratadine","slug":"desloratadine","company":"Merck Sharp Dohme"},{"name":"fexofenadine","slug":"fexofenadine","company":"Sanofi Aventis Us"}],"globalPrevalence":68000000}],"mechanism":{"target":"Histamine H1 receptor","targets":[{"gene":"HRH1","source":"DrugCentral","target":"Histamine H1 receptor","protein":"Histamine H1 receptor","isPrimary":true,"activityType":"Ki","activityValue":8},{"gene":"HTR2A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2A","protein":"5-hydroxytryptamine receptor 2A"},{"gene":"ADRA2C","source":"DrugCentral","target":"Alpha-2C adrenergic receptor","protein":"Alpha-2C adrenergic receptor"},{"gene":"DRD3","source":"DrugCentral","target":"D(3) dopamine receptor","protein":"D(3) dopamine receptor"},{"gene":"HTR1A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 1A","protein":"5-hydroxytryptamine receptor 1A"},{"gene":"DRD2","source":"DrugCentral","target":"D(2) dopamine receptor","protein":"D(2) dopamine receptor"},{"gene":"SLC6A3","source":"DrugCentral","target":"Sodium-dependent dopamine transporter","protein":"Sodium-dependent dopamine transporter"},{"gene":"CHRM4","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M4","protein":"Muscarinic acetylcholine receptor M4"},{"gene":"HTR2C","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2C","protein":"5-hydroxytryptamine receptor 2C"},{"gene":"CHRM3","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M3","protein":"Muscarinic acetylcholine receptor M3"}],"modality":"Small Molecule","drugClass":"ebastine","explanation":"","oneSentence":"","technicalDetail":"Ebastine acts as a competitive antagonist at the histamine H1 receptor, inhibiting the binding of histamine and reducing the downstream effects of histamine release, such as vasodilation, increased vascular permeability, and smooth muscle contraction."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/977","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=EBASTINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=EBASTINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:51:07.633979","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:50:35.102118+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"cyproheptadine","drugSlug":"cyproheptadine","fdaApproval":"1961-10-17","genericCount":31,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"antazoline","drugSlug":"antazoline","fdaApproval":"1990-04-30","relationship":"same-class"},{"drugName":"triprolidine","drugSlug":"triprolidine","fdaApproval":"1983-05-17","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"azatadine","drugSlug":"azatadine","fdaApproval":"1977-03-29","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"astemizole","drugSlug":"astemizole","fdaApproval":"1988-12-31","relationship":"same-class"},{"drugName":"terfenadine","drugSlug":"terfenadine","fdaApproval":"","relationship":"same-class"},{"drugName":"loratadine","drugSlug":"loratadine","fdaApproval":"1993-04-12","genericCount":29,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"ketotifen","drugSlug":"ketotifen","fdaApproval":"1999-07-02","patentExpiry":"Mar 27, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"acrivastine","drugSlug":"acrivastine","fdaApproval":"1994-03-25","relationship":"same-class"},{"drugName":"azelastine","drugSlug":"azelastine","fdaApproval":"1996-11-01","patentExpiry":"Jun 4, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"epinastine","drugSlug":"epinastine","fdaApproval":"2003-10-16","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"fexofenadine","drugSlug":"fexofenadine","fdaApproval":"1996-07-25","patentExpiry":"Aug 2, 2030","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"desloratadine","drugSlug":"desloratadine","fdaApproval":"2001-12-21","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"ebastine","indications":{"approved":[{"name":"Allergic rhinitis","source":"DrugCentral","snomedId":61582004,"regulator":"FDA"},{"name":"Chronic idiopathic urticaria","source":"DrugCentral","snomedId":302162004,"regulator":"FDA","usPrevalence":null,"globalPrevalence":68000000,"prevalenceMethod":"curated","prevalenceSource":"Allergy, 2020 (PMID:31494963)"}],"offLabel":[],"pipeline":[]},"_fixedFields":["primaryTarget"],"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"cyproheptadine","brandName":"cyproheptadine","genericName":"cyproheptadine","approvalYear":"1961","relationship":"same-class"},{"drugId":"antazoline","brandName":"antazoline","genericName":"antazoline","approvalYear":"1990","relationship":"same-class"},{"drugId":"triprolidine","brandName":"triprolidine","genericName":"triprolidine","approvalYear":"1983","relationship":"same-class"},{"drugId":"azatadine","brandName":"azatadine","genericName":"azatadine","approvalYear":"1977","relationship":"same-class"},{"drugId":"astemizole","brandName":"astemizole","genericName":"astemizole","approvalYear":"1988","relationship":"same-class"},{"drugId":"terfenadine","brandName":"terfenadine","genericName":"terfenadine","approvalYear":"","relationship":"same-class"},{"drugId":"loratadine","brandName":"loratadine","genericName":"loratadine","approvalYear":"1993","relationship":"same-class"},{"drugId":"ketotifen","brandName":"ketotifen","genericName":"ketotifen","approvalYear":"1999","relationship":"same-class"},{"drugId":"acrivastine","brandName":"acrivastine","genericName":"acrivastine","approvalYear":"1994","relationship":"same-class"},{"drugId":"azelastine","brandName":"azelastine","genericName":"azelastine","approvalYear":"1996","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05815602","phase":"PHASE3","title":"Ebastine Versus Mebeverine in IBS Patients","status":"RECRUITING","sponsor":"Guy Boeckxstaens","startDate":"2023-03-30","conditions":["IBS - Irritable Bowel Syndrome","IBS"],"enrollment":200,"completionDate":"2028-01-01"},{"nctId":"NCT07114055","phase":"PHASE2,PHASE3","title":"Effect of Ebastine in Patients With Diarrhea Predominant Irritable Bowel Syndrome","status":"RECRUITING","sponsor":"Md. Hazrat Ali","startDate":"2025-08-15","conditions":["Irritable Bowel Syndrome - Diarrhoea"],"enrollment":60,"completionDate":"2026-07"},{"nctId":"NCT07114107","phase":"NA","title":"Vibroacoustic Therapy With Oscillating Positive Expiratory Pressure in the Treatment of Nasal Congestion","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-08","conditions":["Atopic Rhinitis","Atopic Asthma"],"enrollment":200,"completionDate":"2026-05"},{"nctId":"NCT06480110","phase":"PHASE1,PHASE2","title":"Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2024-06-20","conditions":["Metastatic Castration-resistant Prostate Cancer"],"enrollment":30,"completionDate":"2027-12-01"},{"nctId":"NCT01908465","phase":"PHASE4","title":"Peripheral Histamine 1 Receptor Blockade in IBS: Multicenter Trial","status":"COMPLETED","sponsor":"KU Leuven","startDate":"2013-11","conditions":["Irritable Bowel Syndrome (IBS)"],"enrollment":200,"completionDate":"2022-11-02"},{"nctId":"NCT01144832","phase":"PHASE4","title":"Irritable Bowel Syndrome (IBS) Treatment With H1-receptor Antagonists","status":"COMPLETED","sponsor":"KU Leuven","startDate":"2009-10","conditions":["Irritable Bowel Syndrome"],"enrollment":55,"completionDate":"2012-05"},{"nctId":"NCT02065440","phase":"NA","title":"The Effect of Ebastine/Pseudoephedrine on Subacute Cough","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2011-09","conditions":["Cough"],"enrollment":130,"completionDate":""},{"nctId":"NCT01940393","phase":"PHASE4","title":"Evaluation of the Inhibitory Effect of 5 Anti-Histamines in Urticaria","status":"COMPLETED","sponsor":"Grupo de Alergología Clínica y Experimental","startDate":"2013-08","conditions":["Urticaria"],"enrollment":150,"completionDate":"2014-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"007136","UNII":"TQD7Q784P1","CHEBI":"CHEBI:31528","INN_ID":"5633","RXNORM":"23796","UMLSCUI":"C0058895","chemblId":"CHEMBL305660","ChEMBL_ID":"CHEMBL305660","KEGG_DRUG":"D01478","DRUGBANK_ID":"DB11742","PUBCHEM_CID":"3191","MESH_SUPPLEMENTAL_RECORD_UI":"C058249"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":366,"therapeuticAreas":["Immunology"],"atcClassification":{"source":"DrugCentral","atcCode":"R06AX22","allCodes":["R06AX22"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 28","pmid":"41833879","title":"Repositioning of nonsedating antihistamine Ebastine for anti-lung adenocarcinoma based on EGFR/ERBB2 dual-targeting strategy.","journal":"European journal of pharmacology"},{"date":"2026 Feb 16","pmid":"41707943","title":"Efficacy and Safety of Oral Antihistamines for Allergic Rhinitis: Network Meta-Analysis.","journal":"The journal of allergy and clinical immunology. In practice"},{"date":"2026 Feb 13","pmid":"41686612","title":"Severe exfoliative dermatitis induced by apalutamide in a mHSPC patient: A case report.","journal":"Medicine"},{"date":"2026 Apr","pmid":"41645758","title":"Ebastine targets HER2/HER3 signaling and cancer stem cell traits to overcome trastuzumab resistance in HER2‑positive breast cancer.","journal":"International journal of molecular medicine"},{"date":"2026 Jan","pmid":"41603723","title":"Dose-Dependent Effect of the Histamine 1 Receptor Antagonist Ebastine in Patients With Non-Constipated Irritable Bowel Syndrome.","journal":"Neurogastroenterology and motility"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"1990","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"OTHER","regulator":"YEAR INTRODUCED","status":"approved","approval_date":"1990-01-01T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:50:35.102118+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}